Pliant Therapeutics, Inc. - PLRX STOCK NEWS

Pliant Therapeutics, a clinical stage biotechnology company, announced its participation in two upcoming investor conferences. The Citi 16th Annual BioPharma Virtual Conference is set for September 8-9, 2021, where the management team will engage in one-on-one meetings. Following this, the Cantor 2021 Virtual Global Healthcare Conference will occur on September 29, 2021, featuring a presentation by CEO Bernard Coulie at 2:40 p.m. ET, along with additional one-on-one meetings. Pliant is focused on developing therapies for fibrosis, including its lead candidate for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

Pliant Therapeutics (Nasdaq: PLRX) provided an update showing progress in its Phase 1a trial for PLN-74809, with SAD cohorts up to 640 mg and MAD cohorts up to 320 mg completed without safety concerns. The Phase 2a trials for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) are on track for enrollment completion by late 2021 and early 2022, respectively. Financially, the company reported a net loss of $22.8 million for Q2 2021, up from $17.0 million the previous year, driven by increased R&D expenses. Cash reserves stand at $244 million, expected to fund operations into 2023.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a biotechnology company focused on fibrosis treatments, will participate in the 2021 BTIG Virtual Biotechnology Conference from August 9-10, 2021. The company's CEO, Bernard Coulie, will engage in a fireside chat on August 10 at 3:30 p.m. EST. Pliant's lead candidate, PLN-74809, is an oral therapy for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, having received Orphan Drug Designation from the FDA. The company is also advancing treatments for nonalcoholic steatohepatitis through partnerships and has additional preclinical oncology and muscular dystrophy programs.

Pliant Therapeutics (PLRX) provided a corporate update and first quarter financial results on May 10, 2021. The company’s PLN-74809 Phase 2a trials in idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) are on track for enrollment completion by late 2021 and first half of 2022, respectively. The trial aims to evaluate safety, tolerability, and pharmacokinetics. Q1 2021 reported a net loss of $22.9 million, a decline from a net income of $11 million in Q1 2020. As of March 31, 2021, cash reserves stood at $264.1 million, sufficient to support operations into 2023.

Pliant Therapeutics (PLRX), a clinical stage biotechnology firm, announced its participation in the virtual 2021 RBC Capital Markets Global Healthcare Conference on May 18-19, 2021. CEO Bernard Coulie will engage in a fireside chat on May 18 at 4:15 p.m. EDT, alongside the senior management team for one-on-one meetings with investors. The session will be accessible for 90 days on the company’s website. Pliant focuses on developing therapies for fibrosis, with its leading candidate PLN-74809 showing promise for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

Pliant Therapeutics, a clinical stage biotechnology company, will participate in the 20th Annual Needham Healthcare Conference from April 12-15, 2021. CEO Bernard Coulie will join a fireside chat with analyst Joseph Stringer on April 13, 2021, at 12:45 p.m. EDT. The event will be accessible via their website's Investors & Media page and will be available for 90 days. Pliant is focused on novel therapies for fibrosis, with candidates PLN-74809 and PLN-1474 in development for IPF, PSC, and liver fibrosis related to NASH.

Pliant Therapeutics (Nasdaq: PLRX) has resumed its PLN-74809 Phase 2a PET imaging trial, with preliminary results expected in the first half of 2021. The company reported strong progress in their Phase 2a trials for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), anticipated to complete enrollment by late 2021 and early 2022, respectively. Financially, R&D expenses rose to $17.9 million, leading to a net loss of $19.0 million, while cash reserves stood at $276.9 million, sufficient for operations into 2023.

Pliant Therapeutics (Nasdaq: PLRX) announced the successful completion of the Phase 1 trial for PLN-1474, a selective integrin α_vβ₁ inhibitor aimed at treating nonalcoholic steatohepatitis (NASH) with liver fibrosis. The trial, involving 84 healthy volunteers, demonstrated the drug's rapid absorption and tolerability without significant adverse effects. Following the trial, PLN-1474 is now under the stewardship of Novartis, per their 2019 Collaboration and License Agreement, which includes significant milestone payments and royalties for Pliant.

Pliant Therapeutics, a clinical stage biotechnology company focused on fibrosis treatment, has announced participation in key virtual investor events. Management will take part in the Cowen 41st Annual Health Care Conference from March 1-4, 2021, with a panel discussion led by President and CEO Bernard Coulie on March 1 at 10:30 a.m. ET. Additionally, they will engage with investors on March 17 during Citi's 2021 Winter West Coast Biotech Virtual Bus Tour. Pliant's lead drug candidate is PLN-74809, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis.